Overview

This is a Phase 1/2, randomized, controlled, open-label, proof-of-concept study to evaluate the safety and tolerability, local and systemic PK profiles of TNP-2092 administered IA on the basis of vancomycin IV and oral antibiotics therapy in participants with early (within 1 month of TKA) or acute hematogenous (within 3 weeks of infectious symptoms) PJI requiring or not requiring DAIR therapy after TKA.

Eligibility

Inclusion Criteria:

• Early (within 1 month of TKA) or acute hematogenous (within 3 weeks of infectious symptoms) PJI requires or does not require DAIR therapy after TKA.
• Suspected or confirmed PJI was caused by a Gram-positive bacterial infection, including methicillin-resistant and ciprofloxacin-resistant Staphylococcus aureus and Staphylococcus epidermidis, as judged by the investigator.
• Agree to be hospitalized for 2 weeks with local intra-articular injection.
• 18 years of age or older (of either sex) at the time of signing the informed consent form (ICF).
• The implanted prosthetic joint was well fixed.
• No sinus tract that communicates with the prosthesis.
• Body mass index (BMI) ≥ 18 kg/m 2 and ≤ 34 kg/m 2.
• Agree to voluntarily use effective contraception from signing the ICF through 8 weeks after the last dose of investigational product (in case of premature withdrawal from the study) or through completion of the end-of-study visit. Male participants must refrain from donating sperm during this period.

Exclusion Criteria:

• History of hypersensitivity or intolerance to any of the following agents: vancomycin or TNP-2092.
• Definite PJI of Gram-negative infection, fungal infection, or Enterococcus infection, or Mycobacterium infection, or Gram-positive mixed Gram-negative and/or fungal infection.
• Definite systemic infection (sepsis).
• Expected survival less than 2 years.
• Female participant is pregnant, lactating, or has a positive screening/baseline pregnancy test.
• Surgical or medical conditions that, in the opinion of the investigator, could affect the participant's ability to participate in the study, or affect the administration of investigational product, or affect the interpretation of study results, including but not limited to active malignancy, metabolic disease, alcohol or drug abuse, or clinically significant laboratory abnormalities.
• Presence of serious liver, blood, or immune system disorders as evidenced by the

  following

  1. Acute hepatitis of any cause within the past year.
  2. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels > 2 times the upper limit of normal (ULN).
  3. Presence of end-stage liver disease-related manifestations such as ascites or hepatic encephalopathy.
  4. Current or anticipated neutropenia (ie, neutrophil count < 0.5 x 10 9/L).
  5. Chemotherapy for cancer, radiation therapy, or potent noncorticosteroid immunosuppressants (eg, cyclosporine, azathioprine, tacrolimus, immunomodulatory monoclonal antibody therapy, etc) within the past 3 months or corticosteroids (≥ 40 mg prednisone/day) for more than 14 days within 30 days prior to randomization.

• Positive AIDS antibody screening.
• History or evidence of severe renal disease or creatinine clearance < 30 mL/min based on the Cockcroft-Gault formula.
• Systemic antibiotics for more than 3 days within 2 weeks prior to enrollment, except for infections other than PJI that are treated with non-systemic or narrow-spectrum anti-gram-negative antibiotics.
• Rifampicin within 4 weeks prior to enrollment.
• Treatment with an investigational agent within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
• Participants who, in the opinion of the investigator, were unable to comply with the protocol and study drug administration procedures or complete the clinical study.